| A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. | |
| | |
MedLine Citation:
|
PMID: 22304839 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein metabolism and the potential effects on the risk of cardiovascular disease (CVD). We searched PubMed/Scopus for articles regarding apoC-II and its role in lipoprotein metabolism and the risk of CVD. Apolipoprotein C-II is a constituent of chylomicrons, very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein (HDL). Apolipoprotein C-II contains 3 amphipathic α-helices. The lipid-binding domain of apoC-II is located in the N-terminal, whereas the C-terminal helix of apoC-II is responsible for the interaction with lipoprotein lipase (LPL). At intermediate concentrations (approximately 4 mg/dL) and in normolipidemic subjects, apoC-II activates LPL. In contrast, both an excess and a deficiency of apoC-II are associated with reduced LPL activity and hypertriglyceridemia. Furthermore, excess apoC-II has been associated with increased triglyceride-rich particles and alterations in HDL particle distribution, factors that may increase the risk of CVD. However, there is not enough current evidence to clarify whether increased apoC-II causes hypertriglyceridemia or is an epiphenomenon reflecting hypertriglyceridemia. A number of pharmaceutical interventions, including statins, fibrates, ezetimibe, nicotinic acid, and orlistat, have been shown to reduce the increased apoC-II concentrations. An excess of apoC-II is associated with increased triglyceride-rich particles and alterations in HDL particle distribution. However, prospective trials are needed to assess if apoC-II is a CVD marker or a risk factor in high-risk patients. |
| | |
Authors:
|
Anastazia A Kei; Theodosios D Filippatos; Vasilios Tsimihodimos; Moses S Elisaf |
Related Documents
:
|
16196289 - The p53-mediated apoptosis in hypercholesterolemia-induced renal injury of rats. 3728359 - The relationship of dietary fat to plasma lipid levels as studied by factor analysis of... 2738149 - Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the ra... 11290829 - Enhanced dietary fat clearance in postobese women. 11223449 - Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate... 3863729 - Estimation of vldl cholesterol in hyperlipidemia. 14572579 - Origin of oxysterols in hepatic bile of patients with biliary infection. 19344899 - The -1131t>c snp of the apoa5 gene modulates response to fenofibrate treatment in patie... 537979 - Depressed 59 fe absorption due to dietary aflatoxin. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-1 |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: - ISSN: 1532-8600 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-6 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The lack of long-range negative correlations in glucose dynamics is associated with worse glucose co...
Next Document: Ankle and midfoot kinetics during normal gait: A multi-segment approach.